Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.

导出 OA

翻译打印收藏纠错

作者： Mohamed Abdel-Salam,Elgohary ^[1] ; Eman Medhat,Hasan ^[2] ; Amany Ahmad,Ibrahim ^[3] ; Mohamed Farouk Ahmed,Abdelsalam ^[4] ; Raafat Zaher,Abdel-Rahman ^[5] ; Ashraf Ibrahim,Zaki ^[1] ; Mohamed Bakr,Elaatar ^[1] ; Mohamed Thabet,Elnagar ^[1] ; Mohamed Emam,Emam ^[1] ; Mahmoud Moustafa,Hamada ^[1] ; Taimour Mohamed,Abdel-Hamid ^[1] ; Ahmad Samir,Abdel-Hafez ^[1] ; Mohamed Gomaa,Seadawy ^[6] ; Ahmad Rashad,Fatoh ^[1] ; Mohamed Ali,Elsaied ^[1] ; Marwa Abdel-Rahman,Sakr ^[1] ; Ahmed Omar,Elkady ^[1] ; Mohamed Muawad,Shehata ^[1] ; Osama Mohamed,Nawar ^[1] ; Mohamed Abu-Elnaga,Selem ^[1] ; Mohamed Saeed,Abd-Aal ^[1] ; Hany Hafez,Lotfy ^[7] ; Tarek Refaat,Elnagdy ^[8] ; Sherine,Helmy ^[9] ; Magdy Amin,Mubark ^[8]

作者单位： COVID Isolation Department, Almaza Fever Hospital, Cairo, Egypt. ^[1] Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. ^[2] Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ^[3] Clinical Pharmacy Department, Al Galaa Military Medical Complex (GMMC), Cairo, Egypt. ^[4] Virology Department, Central Military Laboratories, Cairo, Egypt. ^[5] Biological Prevention Department, Egyptian Army, Cairo, Egypt. ^[6] Radiology Department, Military Medical Academy, Cairo, Egypt. ^[7] Egyptian Military Medical Services Department, Egyptian Army, Cairo, Egypt. ^[8] Research & Development, PHARCO Pharmaceuticals, Alexandria, Egypt. ^[9]

关键词 SARS-CoV-2 infection effective curing sofosbuvir/ledipasvir